| Title |
Challenging the standard of care in advanced melanoma: focus on pembrolizumab
|
|---|---|
| Published in |
Cancer Management and Research, September 2017
|
| DOI | 10.2147/cmar.s92546 |
| Pubmed ID | |
| Authors |
Raghad M Abdul-Karim, C Lance Cowey |
| Abstract |
The last several years have seen a dramatic rise in the number of effective therapies that have been shown to improve survival outcomes for patients with advanced melanoma. Among these treatments are the immune checkpoint inhibitors, a new class of immunotherapy, that have demonstrated the ability to improve both response rates and survival outcomes. Pembrolizumab, an immune checkpoint inhibitor that blocks the negative regulatory PD-1 receptor on T-cell lymphocytes, has shown improved efficacy compared to standard therapies with an acceptable tolerability profile. Additionally, this agent is being evaluated in adjuvant and combination trial strategies that have great potential to further advance outcomes. This review focuses on the advances that pembrolizumab has made in melanoma and what studies are upcoming that could change the future of melanoma treatment yet again. |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 20% |
| Researcher | 6 | 20% |
| Student > Bachelor | 4 | 13% |
| Other | 3 | 10% |
| Student > Doctoral Student | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 6 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 27% |
| Biochemistry, Genetics and Molecular Biology | 6 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Nursing and Health Professions | 2 | 7% |
| Immunology and Microbiology | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 8 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2017.
All research outputs
#20,448,386
of 23,003,906 outputs
Outputs from Cancer Management and Research
#1,402
of 2,014 outputs
Outputs of similar age
#276,155
of 316,303 outputs
Outputs of similar age from Cancer Management and Research
#16
of 17 outputs
Altmetric has tracked 23,003,906 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,014 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,303 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.